Authors
Mette Wod, Bente Mertz Nørgård, Erantis Sørensen, Jan Nielsen, Jens Kjeldsen
Published in
Scandinavian journal of gastroenterology. Pages 1-9. Oct 12, 2026. Epub Oct 12, 2026.
Abstract
Most patients with Crohn's disease (CD) or ulcerative colitis (UC) receive medication at diagnosis, but some do not. We examined 25-year trends in the proportion of newly diagnosed IBD patients not receiving any pharmacologic treatment within one or three years of diagnosis.
Using national health registries, we identified all incident CD and UC patients in Denmark from 1996-2020. IBD-specific medication use was captured from one month before diagnosis through one and three years after diagnosis. Patients with no recorded IBD-specific pharmacological treatment were classified as pharmacologically untreated. Proportions were assessed by age at diagnosis (<18, 18-59, ≥60 years) and calendar period.
Among 51,045 incident IBD patients, 21% of those with CD and 12% with UC received no IBD-specific pharmacological treatment within one year of diagnosis. At three years, the corresponding proportions were 16% and 9%. Across calendar periods, the proportion pharmacologically untreated within one year increased from 19% (95% CI 17-21) to 24% (95% CI 22-25) in CD and decreased from 14% (95% CI 12-15) to 10% (95% CI 9-10) in UC. Older patients had the highest proportions.
Approximately one in five patients with CD and one in ten patients with UC received no IBD-specific pharmacological treatment in the first year after diagnosis. Over 25 years, this proportion decreased in UC but remained high in CD, especially in older adults. These findings highlight a substantial pharmacologicallyuntreated subgroup and warrant further investigation of the underlying clinical pathways and long-term outcomes.
PMID:
42861968
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0